NeoGenomics Inc. Common Stock (NEO)

FairStock Score: 59/100 — STEADY

Key Financials

Strengths

• Generates $33 million in annual free cash flow (3.2% yield on market cap)
• Conservative balance sheet with debt-to-equity of just 0.49, providing financial flexibility

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Altman Z-Score of 1.1 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

NeoGenomics Inc. Common Stock is a micro-cap healthcare company valued at $1.0 billion. Revenue stands at $746 million, though the company is currently unprofitable. From a quality standpoint, NeoGenomics shows solid Piotroski F-Score of 6/9 and distressed Altman Z-Score of 1.1 warrants caution. Growth dynamics show revenue growing at 10.6% and profit growth of 35.5%. Our composite FairStock Score of 59/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $33 million in annual free cash flow (3.2% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer